MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

Recruiting

Phase 2

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

Sponsor:

MedRegen LLC

Code:

NCT04646603

Conditions

COVID-19

ARDS, Human

Stem Cells

Regeneration

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MRG-001

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by MedRegen LLC on 2022-02-15.